Literature DB >> 6154767

Role of alloantigens in natural killing. Allogeneic but not autologous tumor biopsy cells are sensitive for interferon-induced cytotoxicity of human blood lymphcoytes.

F T Vánky, S A Argov, S A Einhorn, E Klein.   

Abstract

Blood lymphocytes of patients with solid tumors were assayed for cytotoxicity against autologous and allogeneic primary tumor cells. The lymphocytes killed autologous tumor cells in 7 of 25 cases (28%) and allogeneic tumor cells in 2 of 37 tests (5%). Lymphocytes from healthy donors were rarely cytotoxic for the biopsy cells, which indicates that these cells have low natural kill sensitivity. The autoreactivity that may reflect the immunological recognition of tumor cells was not altered by pretreatment of the effectors with interferon (IF). In contrast, killing of allogeneic tumor biopsy cells was induced by IF in approximately 50% of tests, with the lymphocytes of both the tumor patients and the healthy donors. The mechanism of the alloreactivity is most likely a consequence of IF-induced polyclonal activation of cytotoxic potential and the lymphocytes that are committed to recognize the alloantigens expressed on the particular target manifest the killing function. When the biopsy cells were explanted and kept in culture for 5-6 d, their susceptibility for the lymphocyte damage increased, and they were killed by the IF-treated cells also in autologous combinations. Whether this change in sensitivity is a result of qualitative or quantitative changes in antigen expression or of other changes in the properties of the cell membrane is unknown.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154767      PMCID: PMC2185865          DOI: 10.1084/jem.151.5.1151

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

1.  An antigen-specific component of lectin-mediated cytotoxicity.

Authors:  W R Clark
Journal:  Cell Immunol       Date:  1975-06       Impact factor: 4.868

2.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

3.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

4.  Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas.

Authors:  M Cikes; S Friberg; G Klein
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

5.  Production of interferon by human leukocytes in vitro.

Authors:  H Strander; K Cantell
Journal:  Ann Med Exp Biol Fenn       Date:  1966

6.  Interferon and the interaction of allogeneic normal and immune lymphocytes with L-cells.

Authors:  G J Svet-Moldavsky; I J Chernyakhovskaya
Journal:  Nature       Date:  1967-09-16       Impact factor: 49.962

7.  Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes.

Authors:  P Lindahl; P Leary; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

8.  Lymphocyte-mediated cytotoxicity against tumor cells. I. Con A activated cytotoxic effector cells exhibit immunological specificity.

Authors:  J D Waterfield; E M Waterfield; G Möller
Journal:  Cell Immunol       Date:  1975-06       Impact factor: 4.868

9.  Indications of cellular immunological reactions against autochthonous tumour in cancer patients studied in vitro.

Authors:  J Stjernsward; P Clifford; S Singh; E Svedmyr
Journal:  East Afr Med J       Date:  1968-07

10.  The influence of different isolation procedures and the use of target cells from melanoma cell lines and short-term cultures on the non-specific cytotoxic effects of lymphocytes from healthy donors.

Authors:  J E de Vries; M Meyering; A van Dongen; P Rümke
Journal:  Int J Cancer       Date:  1975-03-15       Impact factor: 7.396

View more
  34 in total

1.  Autologous tumor killing and natural cytotoxic activity of tumor-associated macrophages in cancer patients.

Authors:  E Yanagawa; A Uchida; M Moore; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

Review 2.  Natural killer cells in resistance to virus-infected cells.

Authors:  B Rager-Zisman; B R Bloom
Journal:  Springer Semin Immunopathol       Date:  1982

Review 3.  Lymphocyte-mediated lysis of tumor cells in vitro. Antigen-restricted clonal and unrestricted polyclonal effects.

Authors:  E Klein
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Clinical and immunological studies of human fibroblast interferon.

Authors:  K Ezaki; M Ogawa; K Okabe; K Abe; K Inoue; N Horikoshi; J Inagaki
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Activation of lymphocyte anti-tumor responses in man. Towards an understanding of effector cell heterogeneity?

Authors:  B M Vose
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 6.  Tumor cells do not arise frequently.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Human spontaneous lymphocyte-mediated cytotoxicity (SLMC) against malignant and normal tissue-derived target cell lines tested in autologous and allogeneic combinations by the microcytotoxicity assay.

Authors:  M Vilien; M Troye-Blomberg; P Perlmann; H Wolf; F Rasmussen
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 8.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

9.  Human T-cell cultures with selective autotumor reactivity.

Authors:  F Vánky; E Klein
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

10.  The immunological profile of mycosis fungoides.

Authors:  J R Jensen; K Thestrup-Pedersen; S Ahrons; H Zachariae
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.